Result of AGM
September 15 2010 - 2:00AM
UK Regulatory
TIDMMEDG
RNS Number : 6932S
Medgenics Inc
15 September 2010
Medgenics, Inc.
('Medgenics' or the 'Company')
Actions Taken at Annual Meeting of Stockholders
15 September 2010
Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel
technology for the manufacture and delivery of therapeutic proteins continuously
in patients using their own tissue, announces the actions taken at its Annual
Meeting of Stockholders held on 13 September 2010 in New York, New York, USA.
At a duly called meeting, at which a quorum was present in person or by proxy,
the three proposals (as previously announced on 1 September 2010) were brought
before the stockholders and were all passed by a majority of the votes cast.
The first proposal related to the election of directors. Each of the current
directors of the Company, Dr. Eugene A. Bauer, Mr. Gary A. Brukardt, Dr. Andrew
L. Pearlman, Dr. Stephen D. McMurray, Mr. Joel S. Kanter and Dr. Alastair
Clemow, was duly re-elected as a director to serve until the next annual meeting
of stockholders and until his respective successor shall have been duly elected
and qualified.
Pursuant to the second proposal, the stockholders ratified the selection of Kost
Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the
Company's independent registered public accounting firm for the year ended
December 31, 2010.
The stockholders also approved the third proposal, which was an amendment to the
Company's 2006 Stock Incentive Plan to increase the number of shares of the
Company's common stock $0.001 par value per share, of the Company ("Common
Shares") available under the Plan from 48,494,572 Common Shares to 60,500,000
Common Shares.
More detail regarding these actions can be found in the Company's Notice of
Annual Meeting posted on the Company's website (www.medgenics.com). No other
business was brought before the Annual Meeting of the Stockholders.
For further information, contact:
+-----------------------------------------+-----------------------------------------+
| Medgenics, Inc. | Phone: +972 4 902 8900 |
| Dr. Andrew L. Pearlman | |
| | |
+-----------------------------------------+-----------------------------------------+
| Religare Capital Markets (Nominated | Phone: +44 207 444 0800 |
| Adviser) | |
| James Pinner | |
| Derek Crowhurst | |
| | |
+-----------------------------------------+-----------------------------------------+
| SVS Securities plc (Joint Broker) | Phone: +44 207 638 5600 |
| Ian Callaway | |
| | |
+-----------------------------------------+-----------------------------------------+
| Nomura Code Securities PLC (Joint | Phone: +44 207 776 1219 |
| Broker) | |
| Jon Senior | |
+-----------------------------------------+-----------------------------------------+
| De Facto Communications (Investor | Phone : +44 20 7861 3838 |
| Relations) | m.wort@defacto.com a.dunphy@defacto.com |
| Mike Wort | |
| Anna Dunphy | |
+-----------------------------------------+-----------------------------------------+
| Grayling (Investor Relations - US) | +1 646 284 9472 |
| Leslie Wolf-Creutzfeldt | lwolf-creutzfeldt@hfgcg.com |
+-----------------------------------------+-----------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBCGDCRXBBGGS
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024
